Am J Manag Care:研究揭示处方药监测方案的弊端!

2017-08-21 sunshine2015 来宝网

过去几十年,处方药过量造成的死亡人数增加了七倍以上,公共卫生官员称这一流行病是美国历史上最严重的毒品危机。

过去几十年,处方药过量造成的死亡人数增加了七倍以上,公共卫生官员称这一流行病是美国历史上最严重的毒品危机。

正在越来越多的州执行处方药监督计划(PDMP),以解决滥用药物管理计划(PDMP),宾州州立研究小组,包括e南,云峰史,丹尼斯·谢亚,约翰·莫兰等一批研究人员一直在调查其影响。

据宾州州立医院卫生政策与行政助理教授Yun Yun Shi表示,不当的药物滥用不仅影响健康结果,而且还会造成浪费和社会成本上涨。 “越来越多的国家通过州级数据库监控处方药的使用情况,收集处方药的采购数据。”

这些程序使用患者数据库来识别不适当的患者行为(如医生购物),促进药物治疗,并通报旨在打击滥用处方药,特别是阿片样物质的公共卫生举措。

研究人员利用美国人口普查局和疾病预防控制中心的数据,研究了这些方案对1999年至2014年所有药物类别的药物过量死亡率的影响,以及1999年至2010年各自的类别。他们检查了2002年或以后开始运行PDMP的34个州,发现处方药监测计划对药物过量死亡率没有明显影响。此外,PDMP可能实际上有助于使用非法药物和其他(不明)药物的死亡率上升。这些影响集中在PDMP运行五年或更长时间的州。

“关于PDMP的文献一直在积累,但结果并不一致。” “据我们所知,这是第一个分析不同类别药物的过量死亡的研究,具有相对强大的统计模型,灵活地说明了与PDMP无关的药物过量死亡率趋势。”

研究人员惊讶的是,具有较长期PDMP的国家实际上可能会加剧问题,特别是在非法药物使用方面。 “但是,重要的是要注意,我们只看死亡率; PDMPS可能会在其他方面发挥积极的影响,如处方不当,药物相关的急诊室访问,或者更普遍的过度消费。”

“对这些结果的潜在的积极影响,在我们的研究中没有调查,可能最终导致死亡率下降,但在今后的研究中需要加以研究。

研究结果具有若干政策和临床意义,因为即使在目标类别的处方阿片样物质中,PDMP似乎也没有成功地降低过量死亡率。“不幸的是,PDMP可能无法完全解决处方转移,医生购物或其他有问题的行为,在这些计划中,潜在的与毒品有关的非法活动只能通过处方填补来检测。 “此外,PDMP可能会驱使病人远离可以帮助他们解决药物滥用或成瘾的医生。此外,网上药店的快速增长可能会增加个人滥用处方药物的机会。”

研究人员发表在“美国管理护理杂志”上的文章显示,PDMP可能需要结合更全面和面向预防的方法来解决药物过量死亡,例如改善患者对适当药物使用的教育,确保正确使用为具有医疗需求的人提供处方药,扩大治疗方案,为供应商提供疼痛管理教育。

将来,研究团队计划根据具体的程序特征来检查PDMP的有效性,这些功能在不同的状态之间有很大的不同。

原始出处:Young Hee Nam, Dennis G. Shea, Yunfeng Shi, et al. State Prescription Drug Monitoring Programs and Fatal Drug Overdoses. Am J Manag Care. May 26, 2017

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633384, encodeId=5110163338436, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 24 15:06:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235772, encodeId=4fe5235e725e, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 21 19:48:21 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235761, encodeId=346f235e6195, content=药品监测监控.非常重要., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Aug 21 19:04:51 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235753, encodeId=7dbb235e5389, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon Aug 21 17:56:08 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235749, encodeId=5826235e495a, content=继续关注. , beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235747, encodeId=cda7235e4713, content=继续学习. , beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:31 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2018-04-24 AspirantSuo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633384, encodeId=5110163338436, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 24 15:06:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235772, encodeId=4fe5235e725e, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 21 19:48:21 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235761, encodeId=346f235e6195, content=药品监测监控.非常重要., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Aug 21 19:04:51 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235753, encodeId=7dbb235e5389, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon Aug 21 17:56:08 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235749, encodeId=5826235e495a, content=继续关注. , beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235747, encodeId=cda7235e4713, content=继续学习. , beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:31 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 131****1460

    学习了受益匪浅.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1633384, encodeId=5110163338436, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 24 15:06:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235772, encodeId=4fe5235e725e, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 21 19:48:21 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235761, encodeId=346f235e6195, content=药品监测监控.非常重要., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Aug 21 19:04:51 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235753, encodeId=7dbb235e5389, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon Aug 21 17:56:08 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235749, encodeId=5826235e495a, content=继续关注. , beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235747, encodeId=cda7235e4713, content=继续学习. , beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:31 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 1e0f8808m18(暂无匿称)

    药品监测监控.非常重要.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1633384, encodeId=5110163338436, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 24 15:06:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235772, encodeId=4fe5235e725e, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 21 19:48:21 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235761, encodeId=346f235e6195, content=药品监测监控.非常重要., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Aug 21 19:04:51 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235753, encodeId=7dbb235e5389, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon Aug 21 17:56:08 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235749, encodeId=5826235e495a, content=继续关注. , beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235747, encodeId=cda7235e4713, content=继续学习. , beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:31 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 中医痴

    不错的.学习了.谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1633384, encodeId=5110163338436, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 24 15:06:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235772, encodeId=4fe5235e725e, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 21 19:48:21 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235761, encodeId=346f235e6195, content=药品监测监控.非常重要., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Aug 21 19:04:51 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235753, encodeId=7dbb235e5389, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon Aug 21 17:56:08 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235749, encodeId=5826235e495a, content=继续关注. , beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235747, encodeId=cda7235e4713, content=继续学习. , beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:31 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 doctorJiangchao

    继续关注.

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1633384, encodeId=5110163338436, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Apr 24 15:06:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235772, encodeId=4fe5235e725e, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Aug 21 19:48:21 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235761, encodeId=346f235e6195, content=药品监测监控.非常重要., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Aug 21 19:04:51 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235753, encodeId=7dbb235e5389, content=不错的.学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Mon Aug 21 17:56:08 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235749, encodeId=5826235e495a, content=继续关注. , beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:35 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235747, encodeId=cda7235e4713, content=继续学习. , beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 21 17:54:31 CST 2017, time=2017-08-21, status=1, ipAttribution=)]
    2017-08-21 doctorJiangchao

    继续学习.

    0

相关资讯

JAMA子刊:90%的阿片类处方药没必要开!

近日,发表在JAMA子刊JAMA Surgery上的一篇研究揭示:约翰霍普金斯大学的研究发现67-92 %的患者被过度开“阿片类药物”的处方,其中只有不到10%的人会丢弃这些令人上瘾的药品。 为此,专家发出警告:显然医生不知道处方的正确数量;同时患者不知道如何处置过度开的药物。在霍普金斯大学麻醉师、首席研究员Mark Bicket博士看来,许多患者还不知道如何安全地摆脱无用的药物。

网购处方药“方便快捷”令人瞠目

近年来,药品逐渐成为人们网购的“新宠”,通过网络下单,快递小哥很快就能送药上门,越来越多的人以网购取代了到药店或医疗机构购买药品。然而,药品毕竟是一种特殊商品,对于处方药,我国一直没有打开网络销售的闸门。但记者调查发现,在眼下火热的B2C(企业对顾客)医药电商销售中,挟私售卖处方药已经成为潜规则,网购处方药的“方便快捷”令人瞠目。

19个销售经久不衰的重磅药品

近年来,药品价格不断上涨。为了跑赢通货膨胀,并获得进一步创新和业务发展(例如兼并和收购)所需的现金流,制药公司和生物技术公司严重依赖其获准产品的的定价能力。

处方药的副作用能够为犯罪开脱吗?

上周,一名澳大利亚男子杀害了熟睡中的妻子,他将他的犯罪行为部分归因于他服用的安眠药的副作用,结果法院判决增加两年服刑时间,最终该男子被判服刑21年。该名男子拒不认罪的原因是有医生表示多西拉敏(安眠药)会导致一个人做出一些出格的事情。但法官并没有接受该理由,该男子最终被判决有罪。法庭虽然承认被告的判断和情绪控制受到了“失代偿期精神状态”的干扰,但是认为一些恶性因素参与其中导致这个案件变得复杂和严重。

PLoS Med:交叉案例:行人使用处方药与道路交通事故发生的风险性研究

之前已经有一些研究表明药用药物会影响人们的驾驶能力,但是却没有数据显示药物和交通事故之间是否存在某种联系。我们希望通过本次研究探索行人服用药用药物和其承担交通事故风险性之间的关系。实验中使用的数据均来自于法国的3大数据库。实验中使用的为案例交叉设计理念,每个案例以自身为对照,控制时间参数为非变量因子。我们利用Lasso辅助程序实现多变量分析,限制假阳性结果。为了避免非测定时间变量因子的影响,实验中

Int J Clin Pharm:孕期过分谨慎用药反而对有害于胎儿的健康

近日,来自东安格利亚大学药学院的一项新的研究发现,孕妇对处方和非处方药的使用过于谨慎。研究共纳入了1120名女性,对于妊娠常见症状如恶心、泌尿道感染和疼痛,很多参与者并不愿意接受治疗。通过在线调查收集参与者孕期所发生的常见症状的数据。询问参与者药物治疗这些症状有害还是有益以及是否有意避免孕期使用药物,如果是继续询问是哪些药物。结果发现,约四分之三的参与者(76.4 %)的妇女服用过处方或非处方药。